(MedPage Today) -- Shanghai-based biotech company HuidaGene Therapeutics disclosed the death of a child 1 year ago in a trial of an investigational gene-editing therapy for Duchenne muscular dystrophy. Semaglutide (Wegovy) attenuated a proteomics...